News

HCV vaccine candidates have been yielded by the virus genome's high genetic variability, and lacking suitable animal models.

New research shows overweight preschoolers have more frequent asthma symptoms, but inhalers are still effective.

Interventions are lacking for MSDs, which can result in lost time at work and early retirement.

Caffeine may have a role to play in both future Parkinson's disease diagnosis and prevention.

NORD announced that it will commemorate the 35th anniversaries of both its formation and the creation of the Orphan Drug Act with a year-long commemoration.

Catalyst Biosciences announced the initiation and open enrollment of the Phase 2 part of its Phase 2/3 program of marzeptacog alfa (activated), a highly potent, subcutaneously administered Factor VIIa therapy in development for the treatment of hemophilia A and B with inhibitors.

This morning, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Novatris’ eltrombopag (Promacta), a first-line treatment for severe aplastic anemia (SAA).

Recent data have found that the same gene editing platform can disable the defective gene responsible for amyotrophic lateral sclerosis in mice. The therapy, which extended the lifespan of the mouse models by 25%, delayed the onset of the muscle wasting which characterizes the disease.

More parents of children with ADHD report seeking information about the condition from online sources than from the healthcare provider.

The bone marrow stimulant is being considered as a first-line combination therapy for severe aplastic anemia.

The increasing frequency and severity of healthcare-associated outbreaks of C. difficile have been linked to trehalose.

Researchers in Canada say a viral therapy developed to target cancer cells can also be used to target latent HIV-infected cells.

Spark Therapeutics CEO Jeff Marrazzo reassured patients and the medical community he has an obligation to ensure access to the novel gene therapy.

Findings could lead to the development of an approach allowing for a safe, lifelong immunity to HIV.

Can the social and psychological traumas experienced as a teenager increase the likelihood of behavior in later adulthood that risks HIV infection?

The study suggests those with different types of ADHD have impairments in unique brain systems.

Researchers included smaller city, town, and rural residents for the study, noting they were populations previously excluded from US pollution-based studies.

Breastfeeding is associated with lower odds of developing asthma compared to formula than bottle feeding with expressed breast milk.

The label removal was backed by 4 clinical safety trials involving more than 40,000 patients.

A Lenox Hill Hospital dermatologist outlines the threats surrounding, and ideal therapies for, dermatological conditions brought on by pollution.

Results from a phase 1-2, dose escalation study cof a single peripheral infusion of AAV5-hFVIII-SQ in 9 men with severe hemophilia A displayed that changes in the vector and gene resulted in successful gene transfer.

The U.S. FDA has accepted for review the New Drug Application for Azedra (iobenguane I 131) to be indicated for patients with malignant, recurrent and/or unresectable pheochromocytoma and paraganglioma.

A large cohort study finds taking acetaminophen for 29 days or more during pregnancy doubles risk of ADHD in offspring.

HCV genotype 6, the most prevalent in Southeast Asia, resolves with 8 weeks of treatment with direct acting antivirals available in the region.

Relive the 10 biggest headlines in this year of clinical news.

The antibody became the first therapy approved for primary progressive MS in March, but researchers are still considering its place in treatment.

Revisit some of the most popular interviews with physicians and clinicians this past year.

The Dermapace System is intended for adults at least 22 years old, with diabetic foot ulcers lasting more than 30 days.

Drossman explains why he thinks the field of research for irritable bowel syndrome is "wide open" for clinicians.

Brimonidine was previously approved by the FDA in 1996 for the treatment of intraocular pressure reduction in patients with glaucoma.